{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:51:25Z","timestamp":1790214685273,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacc.2026.08.015","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:37:15Z","timestamp":1787924235000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study"],"prefix":"10.1016","author":[{"given":"Jose C.","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-7675","authenticated-orcid":false,"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4940-0876","authenticated-orcid":false,"given":"Gaetano M.","family":"De Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Gun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyrica","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Shastri-Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Averkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Dzupina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lopez-Sendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Lorenzatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimvydas","family":"Slapikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcoli","family":"Cyrille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-3359","authenticated-orcid":false,"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"Bohula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.08.015_bib1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.08.015_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.08.015_bib3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","article-title":"Comparison of time-to-first event and recurrent-event methods in randomized clinical trials","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.08.015_bib4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.117.026229","article-title":"Composite end points in clinical research: a time for reappraisal","volume":"135","author":"Armstrong","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.08.015_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.08.015_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ahj.2023.12.004","article-title":"Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial","volume":"269","author":"Bohula","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.08.015_bib7","first-page":"1068","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei LJL","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jacc.2026.08.015_bib8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.0006-341X.2000.00554.x","article-title":"Nonparametric analysis of recurrent events and death","volume":"56","author":"Ghosh","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.jacc.2026.08.015_bib9","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.08.015_bib10","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1161\/CIR.0000000000001412","article-title":"2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"153","author":"Palaniappan","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.08.015_bib11","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1161\/CIR.0000000000001258","article-title":"Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association","volume":"150","author":"Kazi","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.08.015_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/CIRCULATIONAHA.112.124248","article-title":"Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study","volume":"127","author":"Kohli","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.08.015_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamacardio.2023.0711","article-title":"Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER Trial","volume":"8","author":"Jhund","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.08.015_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2023.01.008","article-title":"Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: the COMPASS trial","volume":"258","author":"Branch","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.08.015_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.08.015_bib16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","article-title":"Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial","volume":"4","author":"Murphy","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.08.015_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.08.015_bib18","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/eurheartj\/ehz778","article-title":"Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics","volume":"41","author":"Boden","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.08.015_bib19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.08.015_bib20","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.08.015_bib21","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.08.015_bib22","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726074401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726074401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:53:38Z","timestamp":1787946818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726074401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"alternative-id":["S0735109726074401"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.08.015","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}